Scarica l'app Stockscreener
36.72
1.29%
-0.48
Dopo l'orario di chiusura:
36.01
-0.71
-1.93%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$37.20
Aprire:
$37.37
Volume 24 ore:
1.08M
Relative Volume:
0.36
Capitalizzazione di mercato:
$5.64B
Reddito:
-
Utile/perdita netta:
$-284.08M
Rapporto P/E:
-15.15
EPS:
-2.4234
Flusso di cassa netto:
$-234.65M
1 W Prestazione:
+2.86%
1M Prestazione:
+5.64%
6M Prestazione:
+217.92%
1 anno Prestazione:
+351.11%
Intervallo 1D:
$35.50
$37.84
Intervallo di 1 settimana:
$35.50
$38.19
Portata 52W:
$3.72
$43.73
Cogent Biosciences Inc Stock (COGT) Company Profile
Nome
Cogent Biosciences Inc
Settore
Industria
Telefono
617-945-5576
Indirizzo
275 WYMAN STREET, WALTHAM
Compare COGT vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
36.72 | 5.71B | 0 | -284.08M | -234.65M | -2.4234 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-10 | Aggiornamento | Stifel | Hold → Buy |
| 2025-11-10 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2025-10-16 | Iniziato | Stifel | Hold |
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-11 | Downgrade | Needham | Buy → Hold |
| 2024-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | Iniziato | Citigroup | Buy |
| 2023-12-11 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-12-08 | Iniziato | JP Morgan | Overweight |
| 2023-04-28 | Iniziato | Robert W. Baird | Outperform |
| 2023-03-27 | Ripresa | H.C. Wainwright | Buy |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-06-28 | Iniziato | Guggenheim | Buy |
| 2021-10-11 | Iniziato | H.C. Wainwright | Buy |
| 2021-06-09 | Ripresa | Jefferies | Buy |
| 2020-12-23 | Iniziato | Piper Sandler | Overweight |
| 2020-10-14 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Cogent Biosciences Inc Borsa (COGT) Ultime notizie
Cogent Biosciences, Inc. $COGT Shares Bought by Candriam S.C.A. - MarketBeat
Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting - Investing News Network
New bezuclastinib data in systemic mastocytosis to debut at AAAAI - Stock Titan
Support Test: Is Cogent Biosciences Inc forming a double bottomWatch List & Short-Term Trading Alerts - baoquankhu1.vn
(COGT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Federated Hermes Inc. Purchases 93,223 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Is FDA Breakthrough Status And Rapid Review For Bezuclastinib Reshaping The Case For Cogent Biosciences (COGT)? - Sahm
Assessing Cogent Biosciences (COGT) Valuation After FDA Breakthrough Therapy And Real Time Oncology Review News - Sahm
Commit To Buy Cogent Biosciences At $25, Earn 17.2% Using Options - Nasdaq
Optimize Financial Inc Buys New Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences FDA Milestones Put Bezuclastinib And Valuation In Focus - Yahoo Finance
Cogent Biosciences (COGT) Advances Bezuclastinib-Sunitinib Combination With Breakthrough Therapy Designation (BTD) - Finviz
Large Biotech Fund Sells Shares of Cogent Biosciences for Over $120M - Yahoo Finance
Cogent Biosciences (NASDAQ:COGT) Cut to Sell at Wall Street Zen - MarketBeat
Strs Ohio Has $596,000 Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences, Inc. (COGT) Stock Analysis: A Biotech Powerhouse with 34.79% Upside Potential - DirectorsTalk Interviews
Fairmount Funds Management LLC Increases Stake in Cogent Bioscie - GuruFocus
Why Is Pfizer Stock Rising Tuesday? - Sahm
Cogent Biosciences announcse U.S. BTD for bezuclastinib - Yahoo Finance
Cogent Biosciences Gains Breakthrough Therapy Designation For Bezuclastinib Combination In GIST - Nasdaq
(COGT) Risk Channels and Responsive Allocation - Stock Traders Daily
Cogent Biosciences stock rises after FDA grants breakthrough therapy status By Investing.com - Investing.com Nigeria
Cogent's New Stomach Cancer Treatment Cuts Progression Risk In Half, Gets Breakthrough Therapy Tag - Benzinga
Cogent Biosciences (COGT) Gains FDA Breakthrough Therapy Designa - GuruFocus
Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) - The Manila Times
New GIST combo cuts progression risk by 50% in Cogent trial - Stock Titan
Retail Surge: What is the long term forecast for Cogent Biosciences Inc stockJuly 2025 Earnings & Precise Swing Trade Alerts - baoquankhu1.vn
Real-Time FDA Review Of Bezuclastinib Combo In GIST Might Change The Case For Investing In Cogent Biosciences (COGT) - Sahm
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Cogent Biosciences Expands HER2 Oncology Footprint With New Early-Stage CGT4255 Trial - TipRanks
Emerald Mutual Fund Advisers Trust Grows Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Director Fairmount Funds Management Llc Sells 3,500,000 Shares - MarketBeat
Fairmount funds sells Cogent Biosciences (COGT) shares worth $127.4 million - Investing.com Canada
Emerald Advisers LLC Increases Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (COGT) Is Up 13.1% After FDA RTOR Nod For Bezuclastinib ComboHas The Bull Case Changed? - Yahoo Finance
Cogent Biosciences (NASDAQ:COGT) Earns Outperform Rating from Wedbush - MarketBeat
Wedbush Reiterates "Outperform" Rating for Cogent Biosciences (C - GuruFocus
Cogent Biosciences Initiates New Drug Application Submission for Bezuclastinib Under Real-Time Oncology Review - marketscreener.com
FDA Greenlights Cogent Biosciences' New Drug Application for GIS - GuruFocus
Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR) - The Manila Times
Cogent Biosciences to Initiate New Drug Application - GlobeNewswire
Campbell & CO Investment Adviser LLC Purchases Shares of 61,634 Cogent Biosciences, Inc. $COGT - MarketBeat
What makes Cogent Biosciences Inc. stock attractive todayQuarterly Profit Review & Expert Verified Movement Alerts - bollywoodhelpline.com
HC Wainwright is bullish on Cogent Biosciences, Inc. (COGT) - MSN
Geopolitics Watch: What are Cogent Biosciences Incs recent SEC filings showingShort Setup & Risk Managed Investment Entry Signals - baoquankhu1.vn
Cogent Biosciences, Inc. (COGT): Investor Outlook on a Biotech Innovator with a 28% Upside Potential - DirectorsTalk Interviews
Why Cogent Biosciences (COGT) Is Up 10.3% After Mapping Bezuclastinib’s Multi-Indication NDA Strategy - Sahm
(COGT) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Assessing Cogent Biosciences (COGT) Valuation After Bezuclastinib FDA NDA Submission - Sahm
Cogent Biosciences (COGT) stock jumps as FDA filing timeline sharpens — what investors watch next - TechStock²
Cogent Biosciences (NASDAQ:COGT) Shares Up 7.1%Still a Buy? - MarketBeat
Cogent Biosciences Inc Azioni (COGT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):